PMI Participants Preparatory/Prototyping Initiative

精确医学是一个宽泛的概念，远远超出了单一使用基因组或其他反映健康和疾病易感性的分子标记的范围。我们是独一无二的，即使在十年前也不是这样；我们的健康和医疗保健必须以比目前更微妙的方式来看待和提供。在新的精密医学计划®(PMI)下，协调计划的发展现在使这一目标变得触手可及。正是本着这种精神，我们提出这项提案，作为直接志愿人员(DV)试点研究的PMI筹备/原型倡议(PI)。 我们动员的团队由个人组成，他们在将这项提议付诸实施所需的不同学科方面拥有出色的成就，并信奉PMI的科学愿景，这形成了实施的基本方法。范德比尔特的领导层将与包括布罗德研究所、Verly(前谷歌生命科学)和密歇根大学在内的协同国家合作伙伴一起发挥领导作用。我们的每个组织都将成为未来中心申请的一部分，因此我们有特别强烈的动机来生产高质量的原型和方法。我们在整个翻译领域对精准医学前景的热情，促进了国际公认的项目的发展，使基因组发现、1-4个临床实施、5，6个群体参与(例如，ResearchMatch、基因向善)以及多机构安全和强大的科学合作(RedCap、IRBShare、加速临床试验协议)得以实现。它激励我们积极参与国家网络，这些网络正在破译人类现象组和基因组之间的相互作用，并积极探索通过这些新知识最迅速地改善健康的方法。它塑造了每个组织中大量投入工作的教职员工的职业生涯。这个RFA的截止日期是我们回应过的最短的时间。我们怀着热情和信心，相信我们有能力在获奖后立即执行-组件都已就位

Precision medicine is a broad concept, going far beyond the singular use of genomic or other molecular markers of health and disease susceptibility. We are unique in ways that were not characterized even a decade ago; our health and healthcare must be viewed and delivered in more nuanced ways than is currently possible. The development of the harmonizing programs under the new Precision Medicine Initiative® (PMI) now puts this goal within reach. It is with this spirit that we submit this proposal to serve as the PMI Preparatory/Prototyping Initiative (or Pi) for the Direct Volunteers (DV) Pilot Studies. The team we have mobilized is made up of individuals who have an outstanding record of accomplishment in the diverse disciplines needed to bring this proposal to life, and who embrace the PMI’s scientific vision, which shapes the essential methodologies of implementation. The leadership will be at Vanderbilt with synergistic national partners including the Broad Institute, Verily (formerly Google Life Sciences), and the University of Michigan. Each of our organizations will also be part of applications for the future Centers, so we have especially strong motivations to produce high quality prototypes and methods. Our passion for the promise of precision medicine, throughout the entire translational spectrum, has catalyzed development of internationally-recognized programs enabling genomic discovery,1–4 clinical implementation,5,6 population engagement (e.g. ResearchMatch, Genes for Good), and multi-institutional secure and robust scientific collaborations (REDCap, IRBshare, Accelerated Clinical Trial Agreement). It inspires our active participation in national networks that are deciphering the interactions of the human phenome and genome and actively exploring ways by which this new knowledge can most swiftly improve health. It has molded the careers of a critical mass of engaged faculty at each organization. This RFA has the shortest time to deadline to which we have ever responded. We do so with enthusiasm and confidence in our ability to execute immediately upon award – the components are in place